Overview of Ovitrelle

Ovitrelle is a highly specialized pharmaceutical product used in fertility treatments to trigger the final phase of egg maturation and release. Its active component, Choriogonadotropin Alfa, is a genetically engineered hormone that mimics the effects of the naturally occurring Luteinizing Hormone (LH) surge. This medication is essential for synchronizing the timing of egg retrieval or insemination during assisted reproductive technology procedures.

Quick Facts

Property	Description
Active Ingredient	Choriogonadotropin Alfa (r-hCG)
Form	Solution for injection (pre-filled syringe/pen)
Pharmacological Class	Gonadotropin / LH Analogue
General Purpose	Triggers final egg maturation and ovulation
Origin	Recombinant / Biosynthetic

What Type of Medicine is Ovitrelle? (Identity and Classification)

Ovitrelle belongs to the Gonadotropins pharmacological class, acting specifically as a Luteinizing Hormone (LH) Analogue to complete the final stage of egg development. This classification confirms the substance is used to provide the critical hormonal stimulus required for reproductive processes. Its official non-proprietary name is Choriogonadotropin Alfa (often designated as r-hCG, or recombinant human chorionic gonadotropin). Choriogonadotropin Alfa replaces the natural surge of LH, differentiating it from older urinary-derived products.

Composition, Origin, and Form of Choriogonadotropin Alfa

The single active ingredient in Ovitrelle is Choriogonadotropin Alfa, which is a recombinant or biosynthetic compound. This recombinant nature ensures its production through DNA technology in cultured cells, yielding a high-purity product. This source guarantees the consistency and quality required for precision fertility treatments. The medication is supplied in a ready-to-use form as a sterile solution for injection within a pre-filled syringe or pen, specifically designed for straightforward subcutaneous injection.

What is the General Purpose of Ovitrelle?

The general purpose of Ovitrelle is to provide a reliable, controlled hormonal trigger to complete the final maturation of the ovarian follicles. By initiating this signal, the medication ensures the eggs are prepared and released (a process known as ovulation) at a precise, predetermined time. A typical use scenario involves administering Ovitrelle in women who have undergone prior treatment to stimulate follicle growth, ensuring the controlled release of the eggs for subsequent procedures like in vitro fertilization (IVF).

Regulatory References

Ovitrelle EPAR

What side effects are possible with Ovitrelle ?

Possible Side Effects and Safety Information

Official safety documents for Ovitrelle (Choriogonadotropin Alfa) summarize adverse reactions based on their frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The following is based on regulatory classifications of observed incidence:

Common (may affect up to 1 in 10 people): Reactions include headache, abdominal pain, nausea, vomiting, and localized reactions at the injection site (such as pain, swelling, or bruising).
Uncommon (may affect up to 1 in 100 people): These include diarrhea, depression, irritability, breast pain, and mild or moderate Ovarian Hyperstimulation Syndrome (OHSS).

Serious Adverse Reactions and Key Risks

The most significant, though rare, safety concern documented in regulatory labeling is Severe Ovarian Hyperstimulation Syndrome (OHSS). A further rare risk is Thromboembolism (the formation of blood clots), which may be associated with severe OHSS.

Time-Related Safety Pattern: Regulatory documents note that symptoms of OHSS may develop rapidly, most often occurring three to seven days after administration.

Contraindications and Safety Limitations

Ovitrelle must not be used in individuals with specific pre-existing conditions as defined in the official labeling. These absolute restrictions include known hypersensitivity to Choriogonadotropin Alfa, presence of certain tumors of the hypothalamus or pituitary gland, existing pregnancy, primary ovarian failure, unexplained vaginal bleeding, specific types of carcinoma (uterine, ovarian, or breast), and ovarian cysts or enlargement not caused by polycystic ovarian disease. This framework establishes the official boundaries for the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Ovitrelle (choriogonadotropin alfa) state that the full effects of an acute overdose are unknown. The single, most significant clinical risk explicitly documented as a possible result of an overdose is the development of Ovarian Hyperstimulation Syndrome (OHSS).

Documented Overdose Manifestations and Risks

Classification	Official Regulatory Information
Potential Manifestation	Ovarian Hyperstimulation Syndrome (OHSS)
Severe Outcomes	Thromboembolic events, acute pulmonary distress, ovarian torsion, and haemoperitoneum (complications of severe OHSS)

Official Emergency Actions Required

If an overdose is suspected or if symptoms of OHSS occur, you must seek immediate medical help. The most common symptoms requiring urgent attention are severe abdominal pain, rapid weight gain, abdominal distension, or difficulty breathing.

Regulatory information mandates that if Severe OHSS occurs, treatment must be stopped, and the patient requires hospitalization for comprehensive observation and appropriate supportive therapy. No specific antidote for choriogonadotropin alfa overdose is listed in the official prescribing information; management focuses on supportive care for the resulting complication.

Therapeutic Uses of Ovitrelle

Ovitrelle (choriogonadotropin alfa) is a medication primarily used in the therapeutic domains of reproductive health, where it plays a critical role in supporting fertility treatments. Its main purpose is to support the final stages of egg maturation and release.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms in two major condition categories: women undergoing assisted reproductive techniques (ART), such as in vitro fertilisation (IVF), and anovulatory or oligo-ovulatory women who rarely or do not ovulate.

In these clinical scenarios, Ovitrelle is relevant for easing symptoms associated with acute or episodic changes, which may assist with inducing ovulation or supporting final follicular maturation and luteinisation. This action supports the process when symptoms become temporarily overwhelming. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms related to systemic imbalance

Regulatory References

European Medicines Agency overview of Ovitrelle

Eligibility and Restrictions for Use

Who can and cannot use Ovitrelle?

Ovitrelle (choriogonadotropin alfa) is intended only for adult women of reproductive age who are undergoing specific fertility treatments. Use is officially permitted for women utilizing Assisted Reproductive Techniques (ART) or those who require ovulation induction following follicular stimulation.

Use is prohibited (contraindicated) for women with specific pre-existing conditions. These contraindications include:

Active cancers, specifically ovarian, uterine, or mammary carcinoma, and tumours of the hypothalamus or pituitary gland.
Primary ovarian failure or reproductive system malformations incompatible with pregnancy.
Active thromboembolic disorders (blood clots).
Ovarian enlargement or cysts not related to polycystic ovarian syndrome, or unexplained gynaecological bleeding.

Furthermore, Ovitrelle is not indicated for use during pregnancy or breastfeeding, nor is it for postmenopausal women. Safety and efficacy have not been established in patients with renal or hepatic impairment. There is no relevant use for this medicine in the pediatric population.

What should I know about interactions with other medicines?

The official regulatory profile for Ovitrelle (Choriogonadotropin Alfa) is defined primarily by the absence of specific interaction studies and a few necessary administration restrictions. Government regulatory documents confirm that no dedicated drug-drug interaction studies have been conducted for this medicine. Consequently, the official labeling does not contain detailed information regarding metabolic (CYP enzyme) or transporter-mediated interactions with other prescription drugs. Furthermore, no clinically significant medicinal product interactions have been reported during general human chorionic gonadotropin (hCG) therapy.

Interaction Category	Regulatory Statement
Drug-Drug Interactions	No specific interaction studies have been performed.
Food, Alcohol, Supplements	Not documented in official labeling.

Two specific interaction-related restrictions are mandatory. First, Ovitrelle must not be mixed with other medicinal products in the same syringe for injection due to administration incompatibility, as compatibility data are not established. Second, the administration of the medicine may interfere with laboratory testing. It can cause a false positive result on immunological serum or urinary hCG pregnancy tests for up to ten days after use. Lastly, specific data regarding the medicine’s pharmacokinetics and interaction relevance in patients with renal or hepatic insufficiency have not been established in regulatory documents.

Mechanism of Action

Ovitrelle (choriogonadotropin alfa) functions as a recombinant human chorionic gonadotropin ( r-hCG) analogue, structurally and functionally mimicking endogenous luteinizing hormone ( LH). Its biological target is the Luteinizing Hormone/Choriogonadotropin Receptor ( LHCGR), a G-protein coupled receptor predominantly expressed on ovarian granulosa and theca cells. Ovitrelle acts as an agonist, binding to the LHCGR and initiating intracellular signaling.

This binding triggers the activation of the Gs G-protein subunit, which, in turn, stimulates adenylyl cyclase. This enzyme catalyzes the conversion of adenosine triphosphate ( ATP) to the secondary messenger cyclic adenosine monophosphate ( cAMP). The elevated cAMP levels activate Protein Kinase A ( PKA). The PKA downstream cascade modulates gene transcription and protein phosphorylation, leading to the resumption of oocyte meiosis and the degradation of the cumulus oophorus matrix. System-level physiological consequences include the induction of final follicular maturation and the initiation of luteinization of the granulosa cells. This luteinization process causes a shift in steroidogenesis, promoting the secretion of progesterone from the ovarian tissue.

Dosage and Administration Information

How to Use Ovitrelle — Official Administration Guidelines

Ovitrelle (choriogonadotropin alfa) is a medication intended for use in adult women and is administered as a single subcutaneous injection (under the skin) per treatment cycle. The treatment is mandatory under the supervision of a physician experienced in fertility management. Patients may only perform self-administration after receiving adequate training and ensuring they have access to expert medical advice.

Official Dosing and Timing

The maximum recommended dose for Ovitrelle is 250 micrograms (one pre-filled syringe or pen). This single injection is to be administered at a precise time: 24 to 48 hours after optimal stimulation of follicular growth is achieved. Optimal follicular growth is typically confirmed by ultrasonographic assessment and/or serum estradiol measurements prior to administration.

Administration Requirements

Procedural Element	Official Instruction
Route of Administration	Subcutaneous use (injection under the skin)
Dosage	Single injection of 250 micrograms (maximum dose)
Preparation	Solution for injection is ready-to-use (no reconstitution needed)
Single-Use Provision	Pre-filled syringe or pen is for single use only

Procedural Summary

Official use requires a sequence of steps: first, the patient must be trained by a healthcare professional for injection technique; second, the physician determines that optimal follicular growth has been achieved; and third, the patient administers the single 250 microgram dose via subcutaneous injection at the designated time (24 to 48 hours after the last dose of stimulating medicine). The drug container must be discarded after one use.

These official instructions establish a controlled treatment protocol, ensuring the drug is used precisely at the required point in the reproductive cycle under direct medical guidance and supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ovitrelle (Choriogonadotropin alfa)

Evidence for Use in Assisted Reproductive Technologies (ART)

Ovitrelle was studied for its use in individuals undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF). The primary research context involved randomized controlled trials (RCTs). Studies focused on outcomes describing episodic or acute changes related to the retrieval of eggs. Specifically, researchers monitored outcomes such as the number of eggs collected and the proportion of those eggs that reached maturity.

Findings describe patterns observed in the studies. In studies where Ovitrelle was compared to other treatments, the findings described patterns of similar measurements of egg maturity and egg retrieval counts in the observed populations. Long-term effects are not fully established beyond the immediate treatment cycle. Follow-up durations were limited in many of these trials, meaning that information about fertility outcomes or tracking of adverse events over many years is not always available from the primary studies.

Evidence for Use in Ovulation Induction (OI) for Anovulatory Women

Ovitrelle was studied for its use in women who experience conditions characterized by fluctuating or episodic manifestations of ovulation (anovulatory or oligo-ovulatory infertility). Research primarily used RCTs to explore the measurements of the treatment on follicular development and ovulation. Studies included populations where ovulation was rare or absent, and researchers examined outcomes related to systemic or functional imbalance.

Studies report how symptoms evolved in the observed populations, focusing on the measures used to confirm ovulation. Findings describe patterns observed in the studies where a measurable ovulatory response was recorded. Evidence is limited for certain groups, and sample sizes were modest in some studies. Data for certain groups remain insufficient, meaning that personalized predictions cannot be made based on these group patterns.

What is Still Uncertain About Ovitrelle

The existing research, while informative, has several limitations that mean the certainty remains low for some of the outcomes explored. Comparative evidence is lacking for all potential alternative treatments and protocols. Evidence quality varies across studies, and findings were mixed in some areas. There is limited information for long-term outcomes beyond the immediate post-treatment period for many patients. Data are still emerging for rare or specialized patient groups. Research is ongoing to address these evidence gaps and to provide a more complete understanding.

Frequently Asked Questions (FAQ)

Common questions about Ovitrelle (FAQ)

Q: Why is Ovitrelle sometimes referred to as the 'trigger shot'?

This medication is often called the 'trigger shot' because its general purpose is to provide a reliable hormonal signal that triggers the final maturation and release of the eggs (ovulation). Ovitrelle is an analogue of Luteinizing Hormone (LH), which is the hormone that naturally causes ovulation in the body.

Q: What is the typical timeline for ovulation or egg retrieval after taking Ovitrelle?

According to official regulatory information, the Ovitrelle injection is timed to be administered 24 to 48 hours after optimal follicular growth has been achieved. For procedures like in-vitro fertilization (IVF), the egg retrieval procedure is commonly scheduled to occur approximately 36 hours after the injection.

Q: How many days after the injection is it usually recommended to take a pregnancy test?

Official product information advises that Ovitrelle may interfere with a serum or urine hCG (pregnancy) test for up to ten days following administration. This is because the active ingredient in Ovitrelle is the same type of hormone measured by pregnancy tests. Taking a test during this period could result in a false positive, so the timing is often adjusted.

Q: Is it normal to feel side effects like mild bloating or tenderness after the Ovitrelle shot?

Yes, regulatory documents list common side effects that include abdominal pain and reactions at the injection site, such as pain, swelling, or bruising. Mild abdominal symptoms, like bloating, can be associated with the ovarian changes that occur during treatment.

Q: Can Ovitrelle be used by women who have polycystic ovary syndrome (PCOS)?

Official product documents indicate that Ovitrelle is not contraindicated for women with ovarian enlargement or cysts caused specifically by polycystic ovarian disease (PCOS). However, close medical monitoring is often necessary because PCOS is a risk factor for Ovarian Hyperstimulation Syndrome (OHSS).

Q: Is the medication designed to be administered by the patient at home?

The official guidelines state that patients may perform self-administration of the injection. This is only permitted after receiving adequate training from a healthcare professional and ensuring that expert medical advice is accessible.

Q: Does Ovitrelle affect the results of other lab tests besides pregnancy tests?

Regulatory information primarily specifies that Ovitrelle may interfere with the immunological determination of serum or urinary hCG (pregnancy) tests. No specific interference with other common laboratory tests is detailed in the official product information.

Q: Is it normal to feel a pinching sensation when injecting Ovitrelle?

Official safety summaries list localized reactions at the injection site, including pain and bruising, as common side effects. While a 'pinching sensation' is not explicitly mentioned, it falls under the type of local discomfort that is commonly reported during or immediately after the subcutaneous injection.

Q: What is the difference between Ovitrelle and Ovidrel?

Ovitrelle and Ovidrel contain the same active pharmaceutical ingredient, which is choriogonadotropin alfa. Both are recombinant human chorionic gonadotropin (r-hCG) products used to trigger final egg maturation.

Q: Is Ovitrelle the same type of medication as Gonal-F or Follistim?

Ovitrelle is classified as a Gonadotropin, but it functions as a Luteinizing Hormone (LH) analogue, which provides the final 'trigger.' In contrast, medications like Gonal-F and Follistim are Follicle Stimulating Hormone (FSH) analogues. While both are Gonadotropins, they have different primary functions during the treatment cycle.

Q: How long does the hCG hormone from Ovitrelle stay in the body/system?

Following a subcutaneous injection, the active ingredient, choriogonadotropin alfa, is eliminated from the body with a mean terminal half-life of approximately 29 to 30 hours. This is the time it takes for half the amount of the hormone to be cleared from the system.

Q: What should I do if I think I missed the exact time to take my Ovitrelle injection?

Official patient instructions emphasize that the injection must be given at the exact date and time determined by the physician. If a dose is missed or if the timing is uncertain, regulatory documents specify that the physician must be contacted for specific guidance.

Q: What are the signs of OHSS (Ovarian Hyperstimulation Syndrome) to watch for after using Ovitrelle?

Symptoms of Ovarian Hyperstimulation Syndrome (OHSS) can include rapid weight gain, lower abdominal pain, nausea or vomiting, and difficulty in breathing. Regulatory documents state that these symptoms warrant immediate medical evaluation.

Q: Is weight gain a known side effect of Ovitrelle?

Regulatory documents mention weight gain as a potential symptom related to the development of Ovarian Hyperstimulation Syndrome (OHSS), which is a complication associated with fertility treatments.

Q: Does Ovitrelle increase the chance of having a multiple pregnancy (like twins or triplets)?

Official product information indicates that there is a higher risk of a pregnancy with more than one fetus (a multiple pregnancy, typically twins) compared to pregnancy resulting from natural conception.

Q: What are the ingredients in Ovitrelle besides the active substance?

Official documentation lists the active substance (choriogonadotropin alfa) and several inactive ingredients, or excipients. These may include substances such as mannitol, phosphoric acid, L-methionine, and Poloxamer 188.

Q: What should I do if I notice an air bubble in the Ovitrelle pre-filled pen?

The official instructions contain specific physical steps that are necessary to remove any air bubbles from the pre-filled pen. These instructions should be followed precisely before administering the injection.

Q: What should be done if I experience a severe allergic reaction to Ovitrelle?

Regulatory documents and patient information indicate that signs of a severe allergic reaction (hypersensitivity) warrant immediate medical attention.

Q: What are the warning signs of a blood clot that are related to Ovitrelle?

Ovitrelle treatment is associated with a risk of Thromboembolism (the formation of blood clots), especially in women with pre-existing risk factors. Regulatory documents indicate that these symptoms, which can be signs of the condition, warrant immediate medical evaluation.

Q: What should a patient know about the potential for ectopic pregnancy with treatments involving Ovitrelle?

Official product information states that women who have damaged fallopian tubes have an increased risk of ectopic pregnancy (pregnancy outside the womb) with fertility treatments. Physicians are advised to perform an early ultrasound to help rule out this possibility.

Q: Is it important to check the expiry date on the Ovitrelle pen before use?

Official patient instructions specify that checking the expiration date on the carton or syringe is necessary prior to use to ensure product quality.

Q: Can Ovitrelle be used in women with a history of thyroid or adrenal dysfunction?

Official regulatory labeling indicates that Ovitrelle is contraindicated (should not be used) in patients who have uncontrolled thyroid or adrenal disease.

Q: Does Ovitrelle need to be warmed up before injection?

Some official patient instructions suggest allowing the pre-filled syringe to adjust to room temperature before administration. This recommendation is intended to help reduce potential discomfort during the injection.

How should Ovitrelle be stored and disposed of?

How to Store and Dispose of Ovitrelle?

Ovitrelle (choriogonadotropin alfa) must be stored under specific conditions to maintain product integrity and safety, as directed by regulatory labeling.

Storage Requirements

The unopened pre-filled syringe or pen must be stored in the refrigerator at a temperature between 2 C and 8 C (36 F and 46 F) and not frozen. The product should remain in its original package to protect from light. It is officially labeled that the medication may be stored outside of refrigeration for a maximum single period of 30 days at or below 25 C, after which it must be discarded if unused. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Ovitrelle is for single use only. The used syringe, needle, and any unused solution must be placed immediately into a designated, puncture-resistant sharps container. Do not dispose of the medicine via wastewater or household garbage; unused product and waste material must be handled in accordance with local requirements.

Ovitrelle